Suzyme325 mg

Established / Guideline-Supported Uses

• Exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis — Suzyme is used to replace deficient pancreatic enzymes and improve digestion of fats, proteins, and carbohydrates.
• Cystic fibrosis with pancreatic insufficiency — Suzyme is a standard component of nutritional management.
• Pancreatic insufficiency following pancreatic surgery (e.g., partial or total pancreatectomy) or total gastrectomy.
• Steatorrhea (fatty, malabsorptive stools) resulting from pancreatic enzyme deficiency.

Other/Adjunct Uses (Supportive Evidence)

• Malabsorption associated with conditions such as celiac disease or somatostatinoma, generally as an adjunct to primary treatment of the underlying condition.
• Functional dyspepsia or non-specific digestive discomfort — used adjunctively in some regional practice, though evidence is weaker than for true pancreatic insufficiency.

Suzyme does not treat the underlying cause of pancreatic insufficiency; it is a replacement therapy for the missing digestive enzymes.

Pancreatin is a standardized enzyme concentrate obtained from mammalian (typically porcine) pancreas. Each dose provides a combination of:

• Lipase — breaks down dietary fats (triglycerides) into fatty acids and glycerol.
• Amylase — breaks down starches into simpler sugars.
• Protease — breaks down proteins into peptides and amino acids.

Pancreatin is available as tablets or capsules; some formulations are enteric-coated to protect the enzymes from inactivation by stomach acid.

Suzyme is a pancreatic enzyme replacement product containing a mixture of lipase, amylase, and protease. It is used to compensate for reduced or absent enzyme secretion by the pancreas, a condition known as exocrine pancreatic insufficiency (EPI).

When the pancreas cannot produce enough digestive enzymes, food is not properly broken down and absorbed, leading to symptoms such as bloating, abdominal discomfort, fatty stools (steatorrhea), weight loss, and deficiency of fat-soluble vitamins. Suzyme supplies these enzymes exogenously so that fats, proteins, and carbohydrates can be digested and absorbed more normally.

Suzyme is taken by mouth with meals and snacks, timed to coincide with food intake for maximum effectiveness.

Suzyme belongs to the therapeutic class of digestive enzyme preparations / pancreatic enzyme replacement therapy (PERT).

Pancreatin works by replacing the digestive enzymes that the pancreas would normally secrete into the small intestine. It contains three main enzyme classes:

• Lipase hydrolyzes dietary triglycerides into free fatty acids and monoglycerides, which can then be absorbed.
• Amylase hydrolyzes starch into dextrins and simple sugars (maltose, glucose).
• Protease hydrolyzes proteins into peptides and free amino acids, and also helps degrade certain regulatory peptides in the gut lumen.

Enteric-coated forms of Pancreatin are designed to resist degradation by gastric acid and dissolve in the more alkaline environment of the duodenum, releasing active enzymes where digestion of nutrients primarily occurs. Pancreatin acts locally within the gastrointestinal tract and is not intended to be systemically absorbed in significant amounts.

Suzyme should be taken by mouth, with or immediately after meals and snacks. Swallow whole with adequate liquid; avoid crushing or chewing unless the specific product is formulated to be opened and mixed with soft food, in which case it should not be chewed. Do not retain the drug in the mouth.

• Acid-reducing agents (antacids containing calcium carbonate or magnesium hydroxide): may reduce the effectiveness of enteric-coated Suzyme by causing premature dissolution of the enteric coating in the stomach; separate dosing or use caution when co-administered.
• Iron supplements: pancreatic enzyme products may theoretically reduce the absorption of oral iron; monitor if used together long-term.
• Acarbose/miglitol (alpha-glucosidase inhibitors): Suzyme's amylase activity may theoretically reduce the effect of these agents by increasing carbohydrate breakdown; clinical significance is not well established.

Suzyme is not known to be a substrate, inhibitor, or inducer of hepatic cytochrome P450 enzymes, so systemic drug-drug interactions are unlikely given its local gastrointestinal action.

Side effects of Suzyme are generally dose-related and mostly gastrointestinal:

• Common: abdominal pain/discomfort, nausea, vomiting, diarrhea or loose stools, bloating.
• Less common: oral or perianal irritation/soreness (especially if tablets/capsules are chewed or held in the mouth), hypersensitivity reactions such as skin rash, itching, sneezing, or watery eyes.
• Rare but serious (mainly reported with very high doses, especially in children with cystic fibrosis): fibrosing colonopathy (colonic strictures) and hyperuricemia/hyperuricosuria — see Precautions and Warnings.

Pregnancy: Data on the use of Suzyme in human pregnancy are limited. As a locally-acting enzyme product with minimal expected systemic absorption, major fetal risk is not anticipated, but Suzyme should be used during pregnancy only if clearly needed, and the potential benefit should justify the potential risk to the fetus. Consult a physician before use during pregnancy.

Lactation: It is not known whether components of Suzyme are excreted in human milk in clinically significant amounts. Because of its local action and minimal systemic absorption, Suzyme is generally considered acceptable during breastfeeding, but a physician should be consulted, particularly for higher doses or prolonged use.

• Fibrosing colonopathy: Reported rarely with very high doses of pancreatic enzyme products, particularly in children with cystic fibrosis. To minimize this risk, Suzyme should be dosed according to recommended/weight-based guidelines and the maximum recommended dose should not be exceeded without medical reassessment. Report any new or worsening abdominal symptoms, changes in bowel habits, or abdominal pain to a physician promptly.
• Hyperuricemia/hyperuricosuria: High doses of pancreatic enzyme products have been associated with elevated blood or urine uric acid; use with caution in patients with gout, renal impairment, or pre-existing hyperuricemia.
• Porcine-derived product: Suzyme is generally derived from pig pancreas; counsel patients with religious/dietary restrictions on porcine products, and be aware of a theoretical risk of viral transmission from animal-sourced material, though no confirmed cases have been reported with appropriately manufactured products.
• Administration technique: Avoid crushing/chewing tablets/capsules (unless specifically designed otherwise) and avoid prolonged contact with oral mucosa, which can cause irritation and reduced enzyme activity.
• Use the lowest effective dose that controls symptoms (e.g., steatorrhea) and reassess periodically with the physician.

Deliberate or accidental overdose of Suzyme may cause exaggerated gastrointestinal effects (abdominal pain, nausea, vomiting, diarrhea) and, with sustained very high doses, increases the risk of hyperuricemia/hyperuricosuria and fibrosing colonopathy. There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services; management is supportive and symptomatic. Do not attempt to manage a suspected overdose at home without medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Suzyme is used in children with exocrine pancreatic insufficiency (e.g., cystic fibrosis), with dosing individualized and closely monitored by a pediatrician, generally using weight/enzyme-unit-based schemes for enzyme replacement products; conventional Suzyme tablet formulations should be used in children only under direct physician guidance because of the fibrosing colonopathy risk with high doses.

Elderly

No specific dose adjustment is established for elderly patients; use the lowest effective dose and monitor for gastrointestinal tolerance.

Renal Impairment

No well-established dose adjustment is required; monitor uric acid levels if renal impairment coexists, due to the risk of hyperuricemia with high doses.

Hepatic Impairment

No well-established dose adjustment is required for hepatic impairment.

Suzyme is typically used long-term (often lifelong) in chronic conditions causing permanent exocrine pancreatic insufficiency, such as chronic pancreatitis or cystic fibrosis, since the underlying enzyme deficiency does not resolve. In situations of temporary or reversible pancreatic insufficiency (e.g., after certain surgeries), duration is determined by the treating physician based on recovery of pancreatic function and symptom control.

Pancreatin is classified as a digestive/pancreatic enzyme supplement (pancreatic enzyme replacement therapy), combining lipase, amylase, and protease activities.

Pancreatin supplies exogenous lipase, amylase, and protease that mimic the natural secretions of the exocrine pancreas. These enzymes act within the intestinal lumen to hydrolyze dietary fats, starches, and proteins into absorbable units (fatty acids/monoglycerides, simple sugars, and amino acids/peptides, respectively), thereby correcting the maldigestion and malabsorption that occur when the pancreas cannot secrete adequate enzymes on its own.

Suzyme is used in pediatric patients with confirmed exocrine pancreatic insufficiency, most commonly due to cystic fibrosis. Dosing must be carefully individualized on a weight/enzyme-unit basis and should not exceed recommended maximum doses, because children with cystic fibrosis are at particular risk of fibrosing colonopathy with high-dose, prolonged pancreatic enzyme use. Safety and efficacy of conventional non-weight-based Suzyme tablet formulations in infants and very young children have not been well established; a pediatrician should supervise use and dose titration in this age group.